Today: 3 July 2026

Khadija Saeed

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

IonQ stock climbs after $1.8 billion SkyWater deal — terms, collar and what traders watch next

IonQ stock climbs after $1.8 billion SkyWater deal — terms, collar and what traders watch next

New York, Jan 26, 2026, 10:32 — Regular session IonQ shares climbed Monday following its announcement to acquire U.S. semiconductor foundry SkyWater Technology in a roughly $1.8 billion deal. By 10:17 a.m. ET, IonQ was trading 2.3% higher at $48.33, having earlier reached $50.55. SkyWater’s stock jumped 6.3% to $33.28, after topping out at $34.89.
26 January 2026
···
Nvidia stock price rises as NVDA puts $2 billion into CoreWeave, widening AI data-center ties

Nvidia stock price rises as NVDA puts $2 billion into CoreWeave, widening AI data-center ties

New York, Jan 26, 2026, 09:38 EST — Regular session Nvidia shares climbed 1.5% to $187.67 in early Monday trading after the chipmaker revealed a $2 billion investment in cloud provider CoreWeave at $87.20 per share. This move deepens their partnership around new AI data centers. CoreWeave shares surged nearly 10% in premarket action. Nvidia is acquiring about 23 million CoreWeave shares, nearly doubling its previous 6.3% stake, Reuters reports, citing LSEG data.
26 January 2026
····
1 … 379 380 381 382 383 … 878

Stock Market Today

  • Asahi Kasei (TSE:3407) wraps up ¥17.86bn buyback, highlights pharma tech scale-up
    July 3, 2026, 4:32 PM EDT. Asahi Kasei (TSE:3407) finished a ¥17.86 billion buyback, taking in 0.75% of its shares and signaling a focus on returns for shareholders. Peptistar has now launched Asahi Kasei's FO-MD system at the plant level, putting its pharmaceutical concentration tech into real-world production. This push could drive earnings through healthcare and process solutions, adding to its main battery and hydrogen businesses. Some risks remain for executing FO-MD and AK1940 at scale. The stock has moved up, but some see valuation still lagging-with fair value estimates pointing to a possible double from here. The story here is tighter capital discipline and a bigger bet on new technology.
Go toTop